DUBLIN–(BUSINESS WIRE)–The “Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 20 molecules.
Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The latest report outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) – Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal.
It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 11 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes (Juvenile Diabetes), Alzheimer’s Disease, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Osteoarthritis, Pancreatic Diseases and Parkinson’s Disease.
Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects.
Scope
- The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics
Key Topics Covered:
Introduction
Report Coverage
Overview
Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Companies Involved in Therapeutics Development
- ADM Therapeutics
- Adocia SAS
- Eli Lilly and Co
- Gubra ApS
- Intarcia Therapeutics Inc
- Neurimmune Holding AG
- Nordic Bioscience AS
- ProMIS Neurosciences Inc
- reMYND NV
- Wren Therapeutics Ltd
- Zealand Pharma AS
Drug Profiles
(exenatide + glucagon + pramlintide) – Drug Profile
- Product Description
- Mechanism Of Action
- (insulin aspart + pramlintide) – Drug Profile
- (insulin lispro + pramlintide) – Drug Profile
- AC-253 – Drug Profile
- ADM-116 – Drug Profile
- Amylin – Drug Profile
- DACRA-089 – Drug Profile
- GUI-17 – Drug Profile
- GUI-35 – Drug Profile
- ITCA-1061 – Drug Profile
- KBP-056 – Drug Profile
- KBP-088 – Drug Profile
- NI-203 – Drug Profile
- ReS-39 – Drug Profile
- Small Molecules to Inhibit IAPP for Neurodegenerative Diseases and Pancreatic Diseases – Drug Profile
- Synthetic Peptide for Obesity and Type 2 Diabetes – Drug Profile
- Synthetic Peptides to Inhibit ABPP and IAPP for Alzheimer’s Disease and Type 2 Diabetes – Drug Profile
- Synthetic Peptides to Target IAPP for Obesity and Diabetes – Drug Profile
- ZP-5461 – Drug Profile
- ZP-8396 – Drug Profile
Dormant Products
Discontinued Products
Product Development Milestones
Featured News & Press Releases
- Nov 04, 2021: Zealand Pharma announces first subject dosed in phase 1 trial of amylin analogue ZP8396 for the treatment of obesity
- Nov 01, 2021: Zealand Pharma announces presentation of preclinical data on amylin analogue ZP8396 at The Obesity Society Annual Meeting
- Jun 29, 2021: Adocia initiates BC LisPram phase 1 clinical trial in pump for people with type 1 diabetes
- Jun 14, 2019: ADA2019: Find the two Adocia abstracts including the “BioChaperone Glucagon Exenatide” Poster online
- Jun 04, 2019: Adocia presents on BioChaperone Pramlintide Insulin at the American Diabetes Association 79th Scientific Sessions
- Feb 12, 2019: Adocia to present new clinical data on Pramlintide-Prandial Insulin combinations at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
- Sep 05, 2018: Adocia announces positive topline results for the first clinical study of BioChaperone Pramlintide Insulin in people with type 1 diabetes
- Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes
- Apr 03, 2018: Taming an unruly target in diabetes
- Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes
- May 05, 2014: reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
- Apr 10, 2013: Centennial Lecture features research on restoring memory and movement
- Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer’s Disease
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/vh23fo
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900